Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases

Lippe, Bent von der; Sandven, Per; Brubakk, Oddbjørn

doi:10.1016/j.jinf.2005.04.007

Cited by 130 publications

(88 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19 Study characteristics for the 11 included studies are summarised in Table 1. [10][11][12][20][21][22][23][24][25][26][27] A total of 218 patients received linezolid, of whom 148 had evaluable outcomes; the remainder were reported to have been still receiving treatment at the time of publication. All patients were adults, and all were infected with MDR-TB, of whom at least 62 (28%) were infected with XDR-TB strains.…”

Section: Resultsmentioning

confidence: 99%

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]

Cox

Ford

2012

int j tuberc lung dis

126

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]

Cox

Ford

2012

int j tuberc lung dis

126

View full text Add to dashboard Cite

“…In vitro and pharmacogenetic data suggest that oxazolidinones could be useful in management of mycobacterial infection, including MDR TB (29)(30)(31)(32). However, clinical experience with the use of linezolid in the management of mycobacterial infections has been mainly restricted to case reports in nontuberculous mycobacterial diseases (33)(34)(35) and to a few case reports on patients with MDR TB (28,36,37). Cases of 24 patients with mycobacterial infections who were treated with linezolid were recently reviewed (38).…”

Section: Discussionmentioning

confidence: 99%

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Eker¹,

Ortmann²,

Migliori³

et al. 2008

Emerg. Infect. Dis.

123

View full text Add to dashboard Cite

We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany in [2004][2005][2006]. In 177 (4%) of 4,557 culture-positive TB cases, Mycobacterium tuberculosis isolates were identifi ed as MDR TB; an additional 7 (0.15%) met criteria for XDR TB. Of these 184 patients, 148 (80%) were born in countries of the former Soviet Union. In patients with XDR TB, hospitalization was longer (mean ± SD 202 ± 130 vs. 123 ± 81 days; p = 0.015) and resistance to all fi rst-line drugs was more frequent (36% vs. 86%; p = 0.013) than in patients with MDR TB. Seventyfour (40%) of these 184 patients received treatment with linezolid. Treatment success rates ranged from 59% for the entire cohort (59% for MDR TB and 57% for XDR TB) to 87% for those with a defi nitive outcome (n = 125; 89% for MDR TB and 80% for XDR TB). Extensive drug susceptibility testing and availability of second-and third-line drugs under inpatient management conditions permit relatively high treatment success rates in MDR and XDR TB.

show abstract

“…Its MIC for M. tuberculosis is 0.125-1μg/ml (Alcala et al, 2003). It is reported that 100mg/kg once daily appeared to be bacteriostatic or weakly bactericidal, causing approximately 1~1.5 log reduction in bacterial counts over 28 days and that 600mg of linezolid orally twice daily in salvage regimens for MDR-TB has been associated with sputum culture conversion and cure, albeit with frequent dose-or treatment-limiting side effects such as anaemia, thrombocytopenia, and peripheral www.intechopen.com or optic neuropathy (Fortum et al, 2005;Von der Lippe et al, 2006). Linezolid acts as an inhibitor of bacterial ribosomal protein synthesis.…”

Section: Linezolidmentioning

confidence: 99%